Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold Bays

Showing results (11-20 of 77) with videos related to

Pageof 8
Sort By:
Current Opinion in Endocrinology, Diabetes, and Obesity|August 9, 2014
Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunctionHarold Bays
The American Journal of Cardiology|December 7, 2002
Existing and investigational combination drug therapy for high-density lipoprotein cholesterolHarold Bays
Expert Opinion on Investigational Drugs|November 20, 2002
EzetimibeHarold Bays
Obesity Pillars|April 2, 2025
Editorial: Exploring the nuances of obesity in Asian populationsHarold Bays
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 22, 2013
Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes MellitusHarold Bays
Current Atherosclerosis Reports|March 25, 2014
Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradoxHarold Bays
The American Journal of Cardiology|June 14, 2008
Safety of niacin and simvastatin combination therapyHarold Bays
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
Pharmacotherapy of obesity: currently marketed and upcoming agentsHarold Bays, Carlos Dujovne
Current Medical Research and Opinion|September 3, 2015
Adiposopathy and epigenetics: an introduction to obesity as a transgenerational diseaseHarold Bays, Wendy Scinta
Expert Opinion on Investigational Drugs|September 13, 2002
Anti-obesity drug developmentHarold Bays, Carlos Dujovne
Pageof 8

Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Current Opinion in Endocrinology, Diabetes, and Obesity|August 9, 2014
Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunctionHarold Bays
The American Journal of Cardiology|December 7, 2002
Existing and investigational combination drug therapy for high-density lipoprotein cholesterolHarold Bays
Expert Opinion on Investigational Drugs|November 20, 2002
EzetimibeHarold Bays
Obesity Pillars|April 2, 2025
Editorial: Exploring the nuances of obesity in Asian populationsHarold Bays
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 22, 2013
Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes MellitusHarold Bays
Current Atherosclerosis Reports|March 25, 2014
Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradoxHarold Bays
The American Journal of Cardiology|June 14, 2008
Safety of niacin and simvastatin combination therapyHarold Bays
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
Pharmacotherapy of obesity: currently marketed and upcoming agentsHarold Bays, Carlos Dujovne
Current Medical Research and Opinion|September 3, 2015
Adiposopathy and epigenetics: an introduction to obesity as a transgenerational diseaseHarold Bays, Wendy Scinta
Expert Opinion on Investigational Drugs|September 13, 2002
Anti-obesity drug developmentHarold Bays, Carlos Dujovne
Pageof 8